Identification
- Summary
Isavuconazonium is a triazole antifungal used for the treatment of invasive aspergillosis and mucormycosis.
- Brand Names
- Cresemba
- Generic Name
- Isavuconazonium
- DrugBank Accession Number
- DB06636
- Background
Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA for the treatment of invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and parenteral formulations. Due to low solubility in water of isavuconazole on its own, the isovuconazonium formulation is favorable as it has high solubility in water and allows for intravenous administration. This formulation also avoids the use of a cyclodextrin vehicle for solubilization required for intravenous administration of other antifungals such as voriconazole and posaconazole, eliminating concerns of nephrotoxicity associated with cyclodextrin. Isovuconazonium has excellent oral bioavailability, predictable pharmacokinetics, and a good safety profile, making it a reasonable alternative to its few other competitors on the market.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Isavuconazonium (DB06636)
- Weight
- Average: 717.77
Monoisotopic: 717.241370179 - Chemical Formula
- C35H35F2N8O5S
- Synonyms
- Isavuconazonium
- External IDs
- BAL-8557
- BAL8557
Pharmacology
- Indication
Indicated in the treatment of invasive aspergillosis and invasive mucormycosis.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Antifungals in the triazole class, such as isavuconazonium, target and inhibit the sterol 14-α-demethylase (Erg11p) which is a key player in the demethylation step of the ergosterol biosynthetic pathway. This inhibition results in a halt in production of ergosterol, a molecule typically found in the membranes of fungi such as Aspergillus, Candida, and Mucorales that plays a role in regulation of membrane integrity, fluidity and permeability. The inhibition of Erg11p also causes the buildup of ergosterol precursors, which are toxic and cause cell death.
- Absorption
When administered intravenously as isavuconazonium, >99% of the prodrug is quickly converted to active isavuconazole (catalyzed by plasma esterases). Oral administration of isavuconazonium shows 98% oral bioavailability, however administration with food results in a 20% decrease in AUC (area under concentration-time curve) as well as decreasing maximum serum concentration (Cmax) by 50% and increasing time to Cmax by 1.5 hours.
- Volume of distribution
450 L
- Protein binding
>99%
- Metabolism
Metabolism is primarily hepatic, with CYP3A4 and CYP3A5 involved in phase I metabolism, followed by modification by uridine diphosphate glucuronosyltransferase (UGT).
- Route of elimination
45% excreted in feces and bile, and 45% excreted in urine as inactive metabolites. Less than 1% of active isavuconazole is excreted unchanged in urine.
- Half-life
80 to 130 hours.
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Isavuconazole, the active moiety of isavuconazonium, is classified as Pregnancy Class C and should be avoided in pregnant women. It was also found to be excreted in breast milk in animal studies in rats, therefore it should be avoided in breastfeeding women.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The metabolism of 1,2-Benzodiazepine can be decreased when combined with Isavuconazonium. Abametapir The serum concentration of Isavuconazonium can be increased when it is combined with Abametapir. Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Isavuconazonium. Abiraterone The metabolism of Isavuconazonium can be decreased when combined with Abiraterone. Acalabrutinib The metabolism of Acalabrutinib can be increased when combined with Isavuconazonium. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Isavuconazonium. Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Isavuconazonium. Adagrasib The metabolism of Adagrasib can be decreased when combined with Isavuconazonium. Afatinib The serum concentration of Afatinib can be increased when it is combined with Isavuconazonium. Albendazole The metabolism of Albendazole can be decreased when combined with Isavuconazonium. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Avoid grapefruit products. Grapefruit is a moderate to strong inhibitor of CYP3A4. Strong CYP3A4 inhibitors are contraindicated with isavuconazonium.
- Avoid St. John's Wort. This herb induces the CYP3A4 metabolism of isavuconazonium and may reduce its serum concentration. Co-administration of isavuconazonium with St. John's Wort is contraindicated.
- Take with or without food. The bioavailability of isavuconazonium is not significantly impacted by food.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Isavuconazonium sulfate 31Q44514JV 946075-13-4 LWXUIUUOMSMZKJ-KLFWAVJMSA-M - Active Moieties
Name Kind UNII CAS InChI Key Isavuconazole prodrug 60UTO373KE 241479-67-4 DDFOUSQFMYRUQK-RCDICMHDSA-N - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Cresemba Capsule 100 mg Oral Avir Pharma Inc 2019-05-02 Not applicable Canada 
Cresemba Capsule 186 mg/1 Oral Astellas Pharma US, Inc. 2015-03-06 2017-01-31 US 
Cresemba Injection, powder, lyophilized, for solution 40 mg/1mL Intravenous Astellas Pharma US, Inc. 2015-03-06 Not applicable US Cresemba Capsule 40 mg/1 Oral Astellas Pharma US, Inc. 2022-11-22 Not applicable US Cresemba Capsule 100 mg/1 Oral Astellas Pharma US, Inc. 2015-11-04 Not applicable US Cresemba Powder, for solution 200 mg / vial Intravenous Avir Pharma Inc 2019-05-31 Not applicable Canada
Categories
- Drug Categories
- Anti-Infective Agents
- Antifungal Agents
- Azole Antifungals
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Inducers
- Cytochrome P-450 CYP3A4 Inducers (strength unknown)
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors (moderate)
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Substrates
- Isavuconazole and Prodrugs
- P-glycoprotein inhibitors
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acid esters
- Alternative Parents
- Phenylpropanes / Benzonitriles / Fluorobenzenes / 2,4-disubstituted thiazoles / Imidolactams / Pyridines and derivatives / Aryl fluorides / Triazoles / Heteroaromatic compounds / Carbamate esters show 14 more
- Substituents
- 1,2,4-triazole / 2,4-disubstituted 1,3-thiazole / Alcohol / Alpha-amino acid ester / Amine / Aromatic alcohol / Aromatic heteromonocyclic compound / Aryl fluoride / Aryl halide / Azacycle show 32 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- organic cation (CHEBI:85978)
- Affected organisms
- Candida albicans and other yeasts
- Aspergillis, Candida and other fungi
Chemical Identifiers
- UNII
- VH2L779W8Q
- CAS number
- 742049-41-8
- InChI Key
- RSWOJTICKMKTER-QXLBVTBOSA-N
- InChI
- InChI=1S/C35H35F2N8O5S/c1-22(33-42-30(18-51-33)25-9-7-24(15-38)8-10-25)35(48,28-14-27(36)11-12-29(28)37)19-45-21-44(20-41-45)23(2)50-34(47)43(4)32-26(6-5-13-40-32)17-49-31(46)16-39-3/h5-14,18,20-23,39,48H,16-17,19H2,1-4H3/q+1/t22-,23?,35+/m0/s1
- IUPAC Name
- 1-[(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-4-[1-({methyl[3-({[2-(methylamino)acetyl]oxy}methyl)pyridin-2-yl]carbamoyl}oxy)ethyl]-1H-1,2,4-triazol-4-ium
- SMILES
- [H]C(C)(OC(=O)N(C)C1=C(COC(=O)CNC)C=CC=N1)[N+]1=CN(C[C@](O)(C2=C(F)C=CC(F)=C2)[C@@]([H])(C)C2=NC(=CS2)C2=CC=C(C=C2)C#N)N=C1
References
- General References
- Rybak JM, Marx KR, Nishimoto AT, Rogers PD: Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent. Pharmacotherapy. 2015 Nov;35(11):1037-51. doi: 10.1002/phar.1652. Epub 2015 Nov 2. [Article]
- Miceli MH, Kauffman CA: Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. Clin Infect Dis. 2015 Nov 15;61(10):1558-65. doi: 10.1093/cid/civ571. Epub 2015 Jul 15. [Article]
- FDA Approved Drug Products: Cresemba (isavuconazonium sulfate) [Link]
- External Links
- KEGG Drug
- D10643
- PubChem Compound
- 6918606
- PubChem Substance
- 310264875
- ChemSpider
- 5293801
- 1608322
- ChEBI
- 85978
- ChEMBL
- CHEMBL1183349
- Wikipedia
- Isavuconazonium
- FDA label
- Download (851 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Recruiting Treatment Invasive Fungal Infections 1 3 Completed Treatment Aspergillosis / Invasive Fungal Infections 2 3 Completed Treatment Candidemia / Candidiasis, Invasive / Fungal Infections 1 3 Terminated Prevention Coronavirus Disease 2019 (COVID‑19) / Invasive Aspergillosis / Severe Acute Respiratory Syndrome Coronavirus 2 1 2 Completed Prevention Acute Myeloid Leukemia / Myelodysplastic Syndrome / Neutropenia 1 2 Completed Treatment Coronavirus Disease 2019 (COVID‑19) / Disseminated mucormycosis / Invasive Aspergillosis 1 2 Completed Treatment Hematological Malignancy / Myeloproliferative Disorders (MPD) 1 2 Recruiting Treatment Central Nervous System Lymphoma 1 2, 3 Completed Prevention Acute Myeloid Leukemia 1 1 Completed Not Available Healthy Adult Volunteers / Pharmacokinetics of Isavuconazole / Pharmacokinetics of Ketoconazole 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Oral 100 mg Capsule Oral 100 mg/1 Capsule Oral 186 mg/1 Capsule Oral 186.3 Mg Capsule Oral 40 mg/1 Injection, powder, for solution Intravenous 200 MG Injection, powder, lyophilized, for solution Intravenous 40 mg/1mL Powder, for solution Intravenous 200 mg / vial Capsule, coated Oral 186.3 mg Injection, powder, lyophilized, for solution Intravenous 200 mg - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US7459561 No 2008-12-02 2020-10-31 US US6812238 No 2004-11-02 2020-10-31 US US10206879 No 2019-02-19 2027-09-14 US US10603280 No 2020-03-31 2027-09-14 US US10812238 No 2020-10-20 2025-10-31 US
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00516 mg/mL ALOGPS logP 1.73 ALOGPS logP 0.52 Chemaxon logS -5.2 ALOGPS pKa (Strongest Acidic) 12.57 Chemaxon pKa (Strongest Basic) 6.45 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 9 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 159.37 Å2 Chemaxon Rotatable Bond Count 15 Chemaxon Refractivity 193.86 m3·mol-1 Chemaxon Polarizability 71.63 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitorInducer
- Curator comments
- Isavuconazonium is a prodrug to Isavuconazole which is the actual CYP3A4 substrate, but it will therefore still participate in CYP3A4 drug interactions when taken.
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Rybak JM, Marx KR, Nishimoto AT, Rogers PD: Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent. Pharmacotherapy. 2015 Nov;35(11):1037-51. doi: 10.1002/phar.1652. Epub 2015 Nov 2. [Article]
- CRESEMBA® (isavuconazonium sulfate) FDA Label [Link]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Inhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Miceli MH, Kauffman CA: Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. Clin Infect Dis. 2015 Nov 15;61(10):1558-65. doi: 10.1093/cid/civ571. Epub 2015 Jul 15. [Article]
Drug created at March 19, 2008 16:42 / Updated at March 24, 2023 20:19